Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Neurocritical Care
Erschienen in: Neurocritical Care 1/2019

29.05.2019 | Special Article

Biospecimens and Molecular and Cellular Biomarkers in Aneurysmal Subarachnoid Hemorrhage Studies: Common Data Elements and Standard Reporting Recommendations

verfasst von: Sherry H.-Y. Chou, R. Loch Macdonald, Emanuela Keller, the Unruptured Intracranial Aneurysms and SAH CDE Project Investigators

Erschienen in: Neurocritical Care | Sonderheft 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Development of clinical biomarkers to guide therapy is an important unmet need in aneurysmal subarachnoid hemorrhage (SAH). A wide spectrum of plausible biomarkers has been reported for SAH, but none have been validated due to significant variabilities in study design, methodology, laboratory techniques, and outcome endpoints.

Methods

A systematic review of SAH biomarkers was performed per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The panel’s recommendations focused on harmonization of (1) target cellular and molecular biomarkers for future investigation in SAH, (2) standardization of best-practice procedures in biospecimen and biomarker studies, and (3) experimental method reporting requirements to facilitate meta-analyses and future validation of putative biomarkers.

Results

No cellular or molecular biomarker has been validated for inclusion as “core” recommendation. Fifty-four studies met inclusion criteria and generated 33 supplemental and emerging biomarker targets. Core recommendations include best-practice protocols for biospecimen collection and handling as well as standardized reporting guidelines to capture the heterogeneity and variabilities in experimental methodologies and biomarker analyses platforms.

Conclusion

Significant variabilities in study design, methodology, laboratory techniques, and outcome endpoints exist in SAH biomarker studies and present significant barriers toward validation and translation of putative biomarkers to clinical use. Adaptation of common data elements, recommended biospecimen protocols, and reporting guidelines will reduce heterogeneity and facilitate future meta-analyses and development of validated clinical biomarkers in SAH.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Chou SH, Robertson CS, Participants in the International Multi-disciplinary Consensus Conference on the Multimodality M. Monitoring biomarkers of cellular injury and death in acute brain injury. Neurocrit Care. 2014;21(Suppl 2):S187–214.CrossRefPubMed
2.
Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009;11:3–14.CrossRefPubMedPubMedCentral
3.
Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9:e1001216.CrossRefPubMedPubMedCentral
4.
Moore HM, Kelly A, McShane LM, Vaught J. Biospecimen reporting for improved study quality (BRISQ). Clin Chim Acta. 2012;413:1305.CrossRefPubMed
5.
6.
Saver JL, Warach S, Janis S, et al. Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project. Stroke. 2012;43:967–73.CrossRefPubMedPubMedCentral
7.
Wagner AK, Ren D, Conley YP, et al. Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury. J Neurosurg. 2007;106:538–47.CrossRefPubMed
8.
Carrette O, Burkhard PR, Hughes S, Hochstrasser DF, Sanchez JC. Truncated cystatin C in cerebrospiral fluid: technical [corrected] artefact or biological process? Proteomics. 2005;5:3060–5.CrossRefPubMed
9.
Hesse C, Larsson H, Fredman P, et al. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res. 2000;25:511–7.CrossRefPubMed
10.
Huhmer AF, Biringer RG, Amato H, Fonteh AN, Harrington MG. Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. Dis Markers. 2006;22:3–26.CrossRefPubMed
11.
Shore PM, Thomas NJ, Clark RS, et al. Continuous versus intermittent cerebrospinal fluid drainage after severe traumatic brain injury in children: effect on biochemical markers. J Neurotrauma. 2004;21:1113–22.CrossRefPubMed
12.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.CrossRefPubMedPubMedCentral
13.
Wiesmann M, Missler U, Hagenstrom H, Gottmann D. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1997;139:1155–60.CrossRefPubMed
14.
Stranjalis G, Korfias S, Psachoulia C, Kouyialis A, Sakas DE, Mendelow AD. The prognostic value of serum S-100B protein in spontaneous subarachnoid haemorrhage. Acta Neurochir (Wien). 2007;149:231–7 (discussion 7–8).CrossRef
15.
Oertel M, Schumacher U, McArthur DL, Kastner S, Boker DK. S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci. 2006;13:834–40.CrossRefPubMed
16.
Kellermann I, Kleindienst A, Hore N, Buchfelder M, Brandner S. Early CSF and serum S100B concentrations for outcome prediction in traumatic brain injury and subarachnoid hemorrhage. Clin Neurol Neurosurg. 2016;145:79–83.CrossRefPubMed
17.
18.
Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care. 2007;6:121–38.CrossRefPubMed
19.
Halawa I, Vlachogiannis P, Amandusson A, et al. Seizures, CSF neurofilament light and tau in patients with subarachnoid haemorrhage. Acta Neurol Scand. 2018;137:199–203.CrossRefPubMed
20.
Lewis SB, Wolper RA, Miralia L, Yang C, Shaw G. Detection of phosphorylated NF-H in the cerebrospinal fluid and blood of aneurysmal subarachnoid hemorrhage patients. J Cereb Blood Flow Metab. 2008;28:1261–71.CrossRefPubMed
21.
Chou SH, Lan J, Esposito E, et al. Extracellular mitochondria in cerebrospinal fluid and neurological recovery after subarachnoid hemorrhage. Stroke. 2017;48:2231–7.CrossRefPubMedPubMedCentral
22.
Provencio JJ. Inflammation in subarachnoid hemorrhage and delayed deterioration associated with vasospasm: a review. Acta Neurochir Suppl. 2013;115:233–8.PubMedPubMedCentral
23.
Weir B, Disney L, Grace M, Roberts P. Daily trends in white blood cell count and temperature after subarachnoid hemorrhage from aneurysm. Neurosurgery. 1989;25:161–5.CrossRefPubMed
24.
Niikawa S, Hara S, Ohe N, Miwa Y, Ohkuma A. Correlation between blood parameters and symptomatic vasospasm in subarachnoid hemorrhage patients. Neurol Med Chir (Tokyo). 1997;37:881–4 (discussion 4–5).CrossRef
25.
Muroi C, Hugelshofer M, Seule M, et al. Correlation among systemic inflammatory parameter, occurrence of delayed neurological deficits, and outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2013;72:367–75 (discussion 75).CrossRefPubMed
26.
Chou SH, Feske SK, Simmons SL, et al. Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res. 2011;2:600–7.CrossRefPubMedPubMedCentral
27.
Chou SH, Feske SK, Atherton J, et al. Early elevation of serum tumor necrosis factor-alpha is associated with poor outcome in subarachnoid hemorrhage. J Investig Med. 2012;60:1054–8.CrossRefPubMedPubMedCentral
28.
Mathiesen T, Edner G, Ulfarsson E, Andersson B. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage. J Neurosurg. 1997;87:215–20.CrossRefPubMed
29.
Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70:534–7.CrossRefPubMedPubMedCentral
30.
Wang L, Gao Z. Expression of MMP-9 and IL-6 in patients with subarachnoid hemorrhage and the clinical significance. Exp Ther Med. 2018;15:1510–4.PubMed
31.
32.
Lindgren C, Hultin M, Koskinen LO, Lindvall P, Borota L, Naredi S. ADMA levels and arginine/ADMA ratios reflect severity of disease and extent of inflammation after subarachnoid hemorrhage. Neurocrit Care. 2014;21:91–101.CrossRefPubMed
33.
Triglia T, Mezzapesa A, Martin JC, et al. Early matrix metalloproteinase-9 concentration in the first 48 h after aneurysmal subarachnoid haemorrhage predicts delayed cerebral ischaemia: an observational study. Eur J Anaesthesiol. 2016;33:662–9.CrossRefPubMed
34.
Hollig A, Stoffel-Wagner B, Clusmann H, Veldeman M, Schubert GA, Coburn M. Time courses of inflammatory markers after aneurysmal subarachnoid hemorrhage and their possible relevance for future studies. Front Neurol. 2017;8:694.CrossRefPubMedPubMedCentral
35.
Chou SH, Lee PS, Konigsberg RG, et al. Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke. 2011;42:3624–7.CrossRefPubMedPubMedCentral
36.
37.
Mack WJ, Mocco J, Hoh DJ, et al. Outcome prediction with serum intercellular adhesion molecule-1 levels after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2002;96:71–5.CrossRefPubMed
38.
Zhong W, Zhang Z, Zhao P, et al. The impact of initial systemic inflammatory response after aneurysmal subarachnoid hemorrhage. Turk Neurosurg. 2017;27:346–52.PubMed
39.
Graetz D, Nagel A, Schlenk F, Sakowitz O, Vajkoczy P, Sarrafzadeh A. High ICP as trigger of proinflammatory IL-6 cytokine activation in aneurysmal subarachnoid hemorrhage. Neurol Res. 2010;32:728–35.CrossRefPubMed
40.
Lenski M, Huge V, Schmutzer M, et al. Inflammatory markers in serum and cerebrospinal fluid for early detection of external ventricular drain-associated ventriculitis in patients with subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2018;31(2):227–33.CrossRef
41.
Kim GH, Kellner CP, Hahn DK, et al. Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008;109:38–43.CrossRefPubMed
42.
Ma C, Zhou W, Yan Z, Qu M, Bu X. Toll-like receptor 4 (TLR4) is correlated with delayed cerebral ischemia (DCI) and poor prognosis in aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2015;359:67–71.CrossRefPubMed
43.
Savarraj JPJ, Parsha K, Hergenroeder GW, et al. Systematic model of peripheral inflammation after subarachnoid hemorrhage. Neurology. 2017;88:1535–45.CrossRefPubMedPubMedCentral
44.
Nakatsuka Y, Shiba M, Nishikawa H, et al. Acute-phase plasma osteopontin as an independent predictor for poor outcome after aneurysmal subarachnoid hemorrhage. Mol Neurobiol. 2018;55(8):6841–9.CrossRefPubMed
45.
Dai JX, Cai JY, Lin Q, et al. Thioredoxin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2016;363:84–9.CrossRefPubMed
46.
Liu H, Liu Y, Zhao J, Liu H, He S. Prognostic value of plasma galectin-3 levels after aneurysmal subarachnoid hemorrhage. Brain Behav. 2016;6:e00543.CrossRefPubMedPubMedCentral
47.
Nishikawa H, Nakatsuka Y, Shiba M, et al. Increased plasma galectin-3 preceding the development of delayed cerebral infarction and eventual poor outcome in non-severe aneurysmal subarachnoid hemorrhage. Transl Stroke Res. 2018;9:110–9.CrossRefPubMed
48.
Frijns CJ, Fijnheer R, Algra A, van Mourik JA, van Gijn J, Rinkel GJ. Early circulating levels of endothelial cell activation markers in aneurysmal subarachnoid haemorrhage: associations with cerebral ischaemic events and outcome. J Neurol Neurosurg Psychiatry. 2006;77:77–83.CrossRefPubMedPubMedCentral
49.
Kumar M, Cao W, McDaniel JK, et al. Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhage. Thromb Haemost. 2017;117:691–9.CrossRefPubMedPubMedCentral
50.
Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105:23–56.CrossRefPubMed
51.
Appel D, Seeberger M, Schwedhelm E, et al. Asymmetric and symmetric dimethylarginines are markers of delayed cerebral ischemia and neurological outcome in patients with subarachnoid hemorrhage. Neurocrit Care. 2018;29(1):84–93.CrossRefPubMed
52.
Schebesch KM, Brawanski A, Bele S, et al. Neuropeptide Y—an early biomarker for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurol Res. 2013;35:1038–43.CrossRefPubMed
53.
Lanterna LA, Rigoldi M, Tredici G, et al. APOE influences vasospasm and cognition of noncomatose patients with subarachnoid hemorrhage. Neurology. 2005;64:1238–44.CrossRefPubMed
54.
Niskakangas T, Ohman J, Niemela M, Ilveskoski E, Kunnas TA, Karhunen PJ. Association of apolipoprotein E polymorphism with outcome after aneurysmal subarachnoid hemorrhage: a preliminary study. Stroke. 2001;32:1181–4.CrossRefPubMed
55.
Leung CHS, Poon WS, Yu LM, Wong GKC, Ng HK. Apolipoprotein E genotype and outcome in aneurysmal subarachnoid hemorrhage. Stroke. 2002;33:548–52.CrossRefPubMed
56.
Juvela S, Siironen J, Lappalainen J. Apolipoprotein E genotype and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110:989–95.CrossRefPubMed
57.
Leclerc JL, Blackburn S, Neal D, et al. Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage. Proc Natl Acad Sci USA. 2015;112:1155–60.CrossRefPubMed
58.
Kantor E, Bayir H, Ren D, et al. Haptoglobin genotype and functional outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2014;120:386–90.CrossRefPubMed
59.
Yarlagadda S, Rajendran P, Miss JC, et al. Cardiovascular predictors of in-patient mortality after subarachnoid hemorrhage. Neurocrit Care. 2006;5:102–7.CrossRefPubMed
60.
Degos V, Apfel CC, Sanchez P, et al. An admission bioclinical score to predict 1-year outcomes in patients undergoing aneurysm coiling. Stroke. 2012;43:1253–9.CrossRefPubMed
61.
Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. 2005;112:2851–6.CrossRefPubMed
62.
van der Bilt I, Hasan D, van den Brink R, et al. Cardiac dysfunction after aneurysmal subarachnoid hemorrhage: relationship with outcome. Neurology. 2014;82:351–8.CrossRefPubMed
63.
Ramappa P, Thatai D, Coplin W, et al. Cardiac troponin-I: a predictor of prognosis in subarachnoid hemorrhage. Neurocrit Care. 2008;8:398–403.CrossRefPubMed
64.
Zhang L, Wang Z, Qi S. Cardiac troponin elevation and outcome after subarachnoid hemorrhage: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2015;24:2375–84.CrossRefPubMed
65.
De Bold AJ. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med. 2009;57:736.CrossRef
66.
Taub PR, Fields JD, Wu AH, et al. Elevated BNP is associated with vasospasm-independent cerebral infarction following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15:13–8.CrossRefPubMedPubMedCentral
67.
Rueffert H, Gumplinger A, Renner C, et al. Search for genetic variants in the ryanodine receptor 1 gene in patients with symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15:410–5.CrossRefPubMed
68.
Jamaluddin MS, Weakley SM, Zhang L, Kougias P, Lin PH, Yao Q, Chen C. miRNAs: roles and clinical applications in vascular disease. Expert Rev Mol Diagn. 2011;11(1):79–89.CrossRefPubMedPubMedCentral
69.
70.
Nilsson OG, Brandt L, Ungerstedt U, Saveland H. Bedside detection of brain ischemia using intracerebral microdialysis: subarachnoid hemorrhage and delayed ischemic deterioration. Neurosurgery. 1999;45:1176–84 (discussion 84–5).CrossRefPubMed
71.
Helmy A, Carpenter KL, Menon DK, Pickard JD, Hutchinson PJ. The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production. J Cereb Blood Flow Metab. 2011;31:658–70.CrossRefPubMed
72.
Hillman J, Milos P, Yu ZQ, Sjogren F, Anderson C, Mellergard P. Intracerebral microdialysis in neurosurgical intensive care patients utilising catheters with different molecular cut-off (20 and 100 kD). Acta Neurochir (Wien). 2006;148:319–24 (discussion 24).CrossRef
73.
Kerner A, Schlenk F, Sakowitz O, Haux D, Sarrafzadeh A. Impact of hyperglycemia on neurological deficits and extracellular glucose levels in aneurysmal subarachnoid hemorrhage patients. Neurol Res. 2007;29:647–53.CrossRefPubMed
74.
Skjøth-Rasmussen J, Schulz M, Kristensen SR, Bjerre P. Delayed neurological deficits detected by an ischemic pattern in the extracellular cerebral metabolites in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg. 2004;100:8–15.CrossRefPubMed
75.
Unterberg AW, Sakowitz OW, Sarrafzadeh AS, Benndorf G, Lanksch WR. Role of bedside microdialysis in the diagnosis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2001;94:740–9.CrossRefPubMed
76.
Hlatky R, Valadka AB, Goodman JC, Contant CF, Robertson CS. Patterns of energy substrates during ischemia measured in the brain by microdialysis. J Neurotrauma. 2004;21:894–906.CrossRefPubMed
77.
Helbok R, Madineni RC, Schmidt MJ, et al. Intracerebral monitoring of silent infarcts after subarachnoid hemorrhage. Neurocrit Care. 2011;14:162–7.CrossRefPubMed
78.
Jacobsen A, Nielsen TH, Nilsson O, Schalen W, Nordstrom CH. Bedside diagnosis of mitochondrial dysfunction in aneurysmal subarachnoid hemorrhage. Acta Neurol Scand. 2014;130:156–63.CrossRefPubMed
79.
Sarrafzadeh A, Haux D, Kuchler I, Lanksch WR, Unterberg AW. Poor-grade aneurysmal subarachnoid hemorrhage: relationship of cerebral metabolism to outcome. J Neurosurg. 2004;100:400–6.CrossRefPubMed
80.
Hutchinson PJ, Jalloh I, Helmy A, et al. Consensus statement from the 2014 International Microdialysis Forum. Intensive Care Med. 2015;41:1517–28.CrossRefPubMedPubMedCentral
81.
Coplin WM, Longstreth WT Jr, Lam AM, et al. Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage. Arch Neurol. 1999;56:1348–52.CrossRefPubMed
82.
Beeftink MM, Ruigrok YM, Rinkel GJ, van den Bergh WM. Relation of serum TNF-alpha and TNF-alpha genotype with delayed cerebral ischemia and outcome in subarachnoid hemorrhage. Neurocrit Care. 2011;15:405–9.CrossRefPubMed
83.
Frontera JA, Provencio JJ, Sehba FA, et al. The role of platelet activation and inflammation in early brain injury following subarachnoid hemorrhage. Neurocrit Care. 2017;26:48–57.CrossRefPubMedPubMedCentral
84.
de Oliveira Manoel AL, van der Jagt M, Amin-Hanjani S, Bambakidis N, Brophy GM, Bulsara K, Claassen J, Connolly S, Hoffer A, Hoh B, Holloway RG, Kelly AG, Mayer SA, Nakaji P, Rabinstein AA, Vajkoczy P, Vergouwen MDI, Woo H, Zipfel G; Suarez JI, on behalf of the Unruptured Aneurysms and SAH–CDE Project Investigators. Common data elements for unruptured cerebral aneurysms and aneurysmal subarachnoid hemorrhage: recommendations from a working group on hospital course and acute therapies—proposal of a multidisciplinary research group. Neurocritical Care 2019.
85.
Hackenberg KAM, Etminan N, Wintermark M, Meyers PM, Lanzino G, Rüfenacht D, Krings T, Huston H III, Rinkel G, Derdey C, on behalf of the Unruptured Aneurysms and SAH CDE Project Investigators. Common data elements for radiological imaging of patients with subarachnoid hemorrhage—proposal of a Multidisciplinary Research Group. Neurocritical Care 2019.
86.
Suarez JI, Sheikh MK, Macdonald RL, Amin-Hanjani S, Brown RD Jr, de Oliveira Manoel AL, Derdeyn C, Etminan N, Keller E, Leroux PD, Mayer SA, Morita A, Rinkel G, Rufennacht D, Stienen, M, Torner J, Vergouwen, MD, Wong GKC, on behalf of the Unruptured Cerebral Aneurysms and SAH CDE Project Investigators. Common data elements for unruptured cerebral aneurysms and subarachnoid hemorrhage clinical research: a National Institute for Neurological Disorders and Stroke, National Library of Medicine, and Neurocritical Care Society Project. Neurocritical Care 2019.
Metadaten
Titel
Biospecimens and Molecular and Cellular Biomarkers in Aneurysmal Subarachnoid Hemorrhage Studies: Common Data Elements and Standard Reporting Recommendations
verfasst von
Sherry H.-Y. Chou
R. Loch Macdonald
Emanuela Keller
the Unruptured Intracranial Aneurysms and SAH CDE Project Investigators
Publikationsdatum
29.05.2019
Verlag
Springer US
Erschienen in
Neurocritical Care / Ausgabe Sonderheft 1/2019
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-019-00725-4

Weitere Artikel der Sonderheft 1/2019

Neurocritical Care 1/2019 Zur Ausgabe

Special Article

Common Data Elements for Unruptured Intracranial Aneurysms and Aneurysmal Subarachnoid Hemorrhage: Recommendations from the Working Group on Hospital Course and Acute Therapies—Proposal of a Multidisciplinary Research Group

Special Article

Prioritization and Timing of Outcomes and Endpoints After Aneurysmal Subarachnoid Hemorrhage in Clinical Trials and Observational Studies: Proposal of a Multidisciplinary Research Group

Special Article

Common Data Elements for Unruptured Intracranial Aneurysm and Subarachnoid Hemorrhage Clinical Research: Recommendations from the Working Group on Long-Term Therapies

Special Article

Definition and Prioritization of Data Elements for Cohort Studies and Clinical Trials on Patients with Unruptured Intracranial Aneurysms: Proposal of a Multidisciplinary Research Group

Special Article

Common Data Elements for Subarachnoid Hemorrhage and Unruptured Intracranial Aneurysms: Recommendations from the Working Group on Subject Characteristics

Introduction

The End of the Tower of Babel in Subarachnoid Hemorrhage: Common Data Elements at Last

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 | Parkinson-Krankheit | Podcast | Nachrichten

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus
Professorin Dr. Claudia Trenkwalder, Neurologin

22.04.2024 | DGIM 2024 | Nachrichten

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

19.04.2024 | AAN-Jahrestagung 2024 | Nachrichten

Hustenstiller lindert Agitation bei Alzheimer
weitere anzeigen

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise